Suven Life Sciences Ltd

Suven Life Sciences Ltd: Trading Window closure from 01 October 2026 till expiry of 48 hours after declaration of unaudited Financial Results for the quarter and half year ended 30 September 2026

Study enrollment update

• 424 patients randomized across USA and Europe.
• Enrollment target was 375 patients.
• LPLV expected by December 2026; DBL by March 2027.
• Topline results expected by May 2027.
• Safety data monitored with no concerns to date.

AGM Details

• 37th AGM held on 25 August 2026 at 11:30 a.m. via VC/OAVM.
• Meeting concluded with e-voting at 12:23 p.m. IST.
• Remote e-voting open 21–24 August 2026; 152 members attended via VC/OAVM.

Key Resolutions

• Ordinary: Adoption of standalone and consolidated financial statements for year ended Mar 31, 2026.
• Ordinary: Reappointment of Prof. Seyed E Hasnain as director liable to rotation.
• Ordinary: Related Party Transaction approving Dr. Madhavi Jasti's office of profit in overseas subsidiaries.
• Special: Re-appointment of Dr. Vajja Sambasiva Rao as Independent Director.
• Special: Variation in utilization of funds raised via preferential issue.

Voting Results

• Item 1 passed with 99.9984% in favour.
• Item 2 passed with 99.9805% in favour.
• Item 3 passed with 99.8262% in favour.
• Item 4 passed with 99.9984% in favour.
• Item 5 passed with 99.9811% in favour.

Related Party Transactions

• RPT approved: Dr. Madhavi Jasti’s appointment to office of profit in overseas subsidiaries.

Director Changes

• Prof. Seyed E Hasnain reappointed as director by rotation.
• Dr. Vajja Sambasiva Rao reappointed as Independent Director.

Other Approvals

• Variation in utilisation of funds raised through preferential issue approved.

Issue Overview

• Type of issue and securities: Preferential Issue; Convertible Warrants.
• Total issue size: Rs 85,764.02 lakhs; no revision or undersubscription reported.
• Main objectives: clinical development through overseas subsidiary; drug discovery R&D.
• CAPEX for new R&D centre; General corporate purposes.

Utilisation of Proceeds

• Utilisation per offer document; no material deviations observed.
• 1(a) clinical development: end-quarter unutilised 12,757.13; utilised 27,242.87.
• During the quarter, utilised 8,364.23.
• 1(b) R&D: end-quarter unutilised 7,812.77; utilised 5,187.23.
• 1(c) CAPEX: end-quarter unutilised 15,039.06; utilised 4,960.94.
• 2 GCP: end-quarter unutilised 9,204.78; utilised 3,559.24.
• Total unutilised proceeds: 44,813.73.
• Transfer to subsidiary for operational ease: 28,994.05 lakhs.
• Deployment of unutilised proceeds: investments into mutual funds and fixed deposits; market value 46,828.97.
• Note: Gains on mutual funds excluded from monitoring scope.
• No lien created on proceeds.

Governance and Compliance

• Approvals: management undertaking and statutory auditor certificates; no material deviations.
• Delay in implementation: not applicable.
• Government/statutory approvals for objects: NA.
• There are no material events or information affecting viability reported.

General Corporate Purpose (GCP)

• GCP utilisation: 707.95; rent, office and R&D labs rent, employee benefits, power and fuel charges.
• Board approval for allocation: resolution dated 06 Aug 2026.

Standalone results

• Revenue from operations Rs 356.58 Lakhs; total income Rs 1,108.94 Lakhs.
• Standalone net loss after tax Rs 1,611.91 Lakhs.
• R&D expenses Rs 1,275.60 Lakhs.
• Employee benefits expense Rs 728.18 Lakhs.
• Total expenses Rs 2,720.85 Lakhs.
• EPS (basic/diluted) Rs (0.61).

Consolidated results

• Consolidated revenue Rs 110.89 Million.
• Consolidated PAT Rs (1,276.10) Million.
• Consolidated EPS Rs (4.84).
• Consolidated R&D and operational expenses Rs 1,360.69 Million.
• Total consolidated expenses Rs 1,387.00 Million.

Capital actions

• ESOP: 133,200 options granted; 271,970 shares allotted.
• Warrant issue: 6,40,02,999 warrants; Rs 85,764.02 Lakhs received.
• Utilisation: Rs 40,950.29 Lakhs utilized; balance Rs 44,813.73 Lakhs.

Annual Report access & KYC updates

• FY2025-26 Annual Report emailed to shareholders with registered email addresses.
• Shareholders without registered emails can access the Annual Report via the company website.
• Web path: https://www.suven.com/annualreports.aspx; QR code and site navigation available.
• Update PAN, KYC, and nomination details with DP/RTA; dividends/payments will be electronic upon update.
• Senior Citizens Investor Cell provides assistance via senior.citizen@kfintech.com; toll-free 1800 3094 006.
• RTA contact for queries: einward.ris@kfintech.com.

Overview

• Standalone BRSR report for FY2025-26 by Suven Life Sciences Limited.
• Primary activity: scientific research and technical services for pharma and life sciences, 100% turnover.
• Reporting boundary: standalone basis; exports account for about 70% of turnover.
• Markets served: national presence in 2 states and 4 international markets.

Key ESG Risks & Opportunities

• Clinical trials pose high cost and regulatory/delay risks; mitigation includes risk assessments, experienced team, recruitment strategies, DSMB oversight.
• Potential financial losses and delays to product launches from trial failures or non-compliance.
• Drug safety monitoring risk; mitigated by independent DSMB oversight and regulatory reporting.
• Opportunity: skilled human capital accelerates R&D and strengthens competitive edge.

Governance & Policy Highlights

• Board oversight of ESG with authority delegated to the Chairman for BRSR matters.
• Key policies: Code of Conduct, Anti-Bribery, Whistleblower, Human Rights, Grievance Redressal; Board approval.
• NABL/GLP/GCP aligned; references to NGRBC framework guiding ESG initiatives.
• Independent assurance: limited assurance on policies by J Sundharesan & Associates.
• No fines or enforcement actions reported in the period.

Social Responsibility & Workforce

• Total workforce: 142 permanent and 39 workers; female representation 28% (permanent) and 5% (workers).
• Board: 2 female directors out of 6; Key Management Personnel: 1 female out of 2.
• 100% health insurance coverage for all employees and workers.
• Well-being spend: 16.47% of revenue in FY2025-26.
• Return-to-work after parental leave: 100% for female permanent employees; adherence to inclusive policies.

Environmental Performance

• GHG emissions: Scope 1 45 tCO2e; Scope 2 1,295.76 tCO2e; total intensity 0.0000188 tCO2e per turnover.
• Energy use: total electricity 6,570 GJ; total fuel 65.7 GJ; total non-renewable energy 6,635.70 GJ; no reported renewables.
• Water: withdrawal 2,007.5 kl; consumption 1,807.5 kl; third-party water 2,007.5 kl.
• Waste: bio-medical 11.172 t; battery 0.175 t; total 11.347 t with incineration disposal.
• CETP treatment and STP-based water reuse; NABL accreditation; GLP/GCP compliance.

Stakeholder Engagement & Complaints

• Stakeholders: shareholders/investors, regulatory bodies, employees, customers, suppliers, local communities.
• Engagement channels: annual/quarterly results, website, email; need-based engagement for regulators and others.
• No complaints/grievances filed under the principles in FY2025-26; grievances policy available online.

Other Notable Metrics

• Sustainable sourcing: 90% of inputs sourced sustainably; 21% from MSMEs, 79% within India.
• Related party transactions: investments with related parties at 100%.
• Affiliations: member of three associations (Ph Pharmaceuticals Export Promotion Council, DSIR, NABL).
• Cybersecurity: Information Technology Security Policy in place; access via published policy link.
• CSR: CSR activity not applicable under the Companies Act; limited information available in this section.
• Assurance: limited assurance on policies; external provider: J Sundharesan & Associates.

AGM Details

• Date and time: 25 August 2026, 11:30 a.m. IST.
• Mode: VC / OAVM.
• Cut-off for e-voting: 18 August 2026.
• E-voting window: 21 Aug 2026 9:00 to 24 Aug 2026 17:00 IST.
• Remote e-voting and AGM join instructions provided.

Resolutions

• Item 1: Ordinary adoption of standalone and consolidated financial statements.
• Item 2: Ordinary re-appointment of Prof. Seyed E Hasnain as Director.
• Item 3: Ordinary RPT approving Dr. Madhavi Jasti appointment in overseas WOS; USD 400,000 initial.
• Item 4: Special re-appointment of Dr. Rao as Independent Director for five years from Jan 2027.
• Item 5: Special approval for variation in utilisation of preferential issue proceeds.

Related Party Transaction

• Dr. Madhavi Jasti to oversee medical affairs for overseas WOS; appointment from Sep 1, 2026.
• Remuneration USD 400,000 per annum initially; aggregate cap USD 1,000,000; payable by WOS.

Independent Directors

• Re-appointment of Dr. Vajja Sambasiva Rao as Independent Director for five years beginning 2027.

Fund Utilisation Variation

• Variation reallocates unutilised proceeds among approved objects; total proceeds unchanged.
• Monitoring Agency CRISIL to continue monitoring utilisation of unutilised proceeds.

Auditor Details

• Statutory Auditor: M/s Karvy & Co; tenure from 33rd to 38th AGM.
• Remuneration disclosure referenced in notes; no amount stated here.